阿可替尼治疗复发或难治性边缘区淋巴瘤患者的2期多中心开放标签试验(ACE-LY-003)
ACE-LY-003是一项2期多中心开放标签试验,评估阿可替尼100 mg每日两次治疗复发/难治性边缘区淋巴瘤(R/R MZL)的疗效与安全性。43例患者中,研究者评估的总体缓解率为53%(95%CI 36%-69%),完全缓解5例(13%),中位无进展生存期(PFS)为27.4个月。阿可替尼在R/R MZL中具有活性且耐受性良好。
要点
- 阿可替尼100 mg每日两次治疗R/R MZL的总体缓解率为53%(95%CI 36%-69%),完全缓解率13%。
- 中位随访13.3个月,估计中位PFS为27.4个月,12个月PFS率为67%。
- 40%患者发生≥3级不良事件,最常见为中性粒细胞减少(14%),未报告房颤/房扑和大出血。
核心结论
- 阿可替尼在复发/难治性边缘区淋巴瘤患者中具有活性且耐受性良好。
研究设计与样本
- 1b/2期试验(NCT02180711)中的2期多中心开放标签R/R MZL队列。
- 43例MZL患者,至少接受过一种 prior 治疗,接受阿可替尼100 mg每日两次直至疾病进展或不可接受毒性。
- 中位年龄69岁(范围42-84),中位既往系统治疗方案数为1(范围1-4)。
- 中位随访13.3个月(范围0.5-45.5)。
主要发现
- 40例可评估患者中,研究者评估的总体缓解率为53%(95%CI 36%-69%),完全缓解5例(13%)。
- 40例(93%)接受治疗的患者出现肿瘤缩小。
- 中位至缓解时间2.9个月,中位缓解持续时间不可估计。
- 估计中位PFS为27.4个月,12个月PFS率为67%。
- 5例患者死亡(疾病进展4例,感染性休克1例)。
关键数值与推荐
- 总体缓解率53%(95%CI 36%-69%),完全缓解率13%。
- 估计中位PFS 27.4个月,12个月PFS率67%。
- ≥3级不良事件发生率40%,中性粒细胞减少14%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acalabrutinib, a Bruton tyrosine kinase inhibitor, demonstrated greater selectivity and improved safety versus ibrutinib in a head-to-head trial in relapsed/refractory (R/R) chronic lymphocytic leukaemia. In the R/R marginal zone lymphoma (MZL) cohort (phase 2) of a phase 1b/2 trial (NCT02180711), 43 patients with MZL and at least one prior therapy received acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity [median age 69 years (range 42-84); median one (1-4) prior systemic regimens]. Median follow-up was 13.3 months (range 0.5-45.5). Among 40 patients evaluable for response, investigator-assessed overall response rate was 53% [95% confidence interval (CI) 36%-69%] with five (13%) complete responses. Tumour reduction occurred in 40 (93%) of the treated patients. Median time to response was 2.9 months (median duration of response not estimable). Estimated median progression-free survival (PFS) was 27.4 months (12-month PFS rate, 67%). Five patients died (disease progression, n = 4; septic shock, n = 1). Seventeen patients (40%) had grade 3 or higher adverse events (AEs), most commonly neutropenia (14%), anaemia, dyspnoea (7% each), fatigue and thrombocytopenia (5% each). Hypertension occurred in 5%; atrial fibrillation/flutter and major haemorrhage were not reported. AEs led to treatment discontinuation in three (7%) patients. Acalabrutinib was active and well tolerated in patients with R/R MZL.
引用
- Strati P, Coleman M, Champion R, et al. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022. PMID: 35861370. doi:10.1111/bjh.18368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。